产品
编 号：F742447
分子式：C65H104N18O26S4
分子量：1681.89
分子式：C65H104N18O26S4
分子量：1681.89
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1092457-65-2
产品详情
生物活性：
Dolcanatide is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research.
体内研究：
Dolcanatide (oral administration; 0.01 and 0.05 mg/kg; once) alleviates TNBS-induced rectal allodynia in rats.Dolcanatide (oral administration; 0.01 and 0.05 mg/kg; once) alleviates stress-induced colorectal hypersensitivity (CRD) in rats.Animal Model:TNBS-induced rectal allodynia in rats
Dosage:0.01 and 0.05 mg/kg
Administration:Oral administration; 0.01 and 0.05 mg/kg; once
Result:Attenuated the TNBS-induced increase in the number of abdominal contractions (distending pressures up to 60 mmHg).
Animal Model:Stress-induced visceral hypersensitivity in Wistar rats
Dosage:0.01 and 0.05 mg/kg
Administration:Oral administration; 0.01 and 0.05 mg/kg; once
Result:Resulted in a significant reduction in the rate of PRS (partial restraint stress)-induced abdominal contractions with increasing CRD (colorectal distension) pressures.
体外研究：
Dolcanatide (0-10 μM; 30 min) activates GC-C receptors to stimulate cGMP synthesis in a dose-dependent manner in T84 cells.Dolcanatide (1 μM; 16 h) suppresses lipopolysaccharide-induced paracellular permeability in Caco-2 and T84 cells.
Dolcanatide is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research.
体内研究：
Dolcanatide (oral administration; 0.01 and 0.05 mg/kg; once) alleviates TNBS-induced rectal allodynia in rats.Dolcanatide (oral administration; 0.01 and 0.05 mg/kg; once) alleviates stress-induced colorectal hypersensitivity (CRD) in rats.Animal Model:TNBS-induced rectal allodynia in rats
Dosage:0.01 and 0.05 mg/kg
Administration:Oral administration; 0.01 and 0.05 mg/kg; once
Result:Attenuated the TNBS-induced increase in the number of abdominal contractions (distending pressures up to 60 mmHg).
Animal Model:Stress-induced visceral hypersensitivity in Wistar rats
Dosage:0.01 and 0.05 mg/kg
Administration:Oral administration; 0.01 and 0.05 mg/kg; once
Result:Resulted in a significant reduction in the rate of PRS (partial restraint stress)-induced abdominal contractions with increasing CRD (colorectal distension) pressures.
体外研究：
Dolcanatide (0-10 μM; 30 min) activates GC-C receptors to stimulate cGMP synthesis in a dose-dependent manner in T84 cells.Dolcanatide (1 μM; 16 h) suppresses lipopolysaccharide-induced paracellular permeability in Caco-2 and T84 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备